Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells

(2017) Francesca Megiorni et al.   Journal of Hematology & Oncology

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer

(2017) Richard Rebello et al.   Genes

KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach

(2016) William JF Green et al.   BRITISH JOURNAL OF CANCER

Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population

(2016) Carmela Ciccarelli et al.   Molecular Cancer

c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines

(2016) G. L. Gravina et al.   RADIATION RESEARCH

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

(2016) Justin Cidado et al.   Oncotarget

Broad targeting of angiogenesis for cancer prevention and therapy

(2015) Zongwei Wang et al.   SEMINARS IN CANCER BIOLOGY

Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model

(2015) A. Aversa et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Progress and controversies: Radiation therapy for prostate cancer

(2014) Neil E. Martin et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells

(2014) L Kyjacova et al.   CELL DEATH AND DIFFERENTIATION

Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay

(2014) FRANCESCO MARAMPON et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer

(2013) Feiyang Liu et al.   ACS Chemical Biology

Trametinib: First Global Approval

(2013) Cameron J. M. Wright et al.   DRUGS

PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer

(2013) Giovanni Luca Gravina et al.   ENDOCRINE-RELATED CANCER

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines

(2013) FRANCESCO MARAMPON et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy

(2012) Gaetano Zafarana et al.   CANCER

Total ERK1/2 activity regulates cell proliferation

(2011) Renaud Lefloch et al.   CELL CYCLE

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

(2011) Davide Torti et al.   EMBO Molecular Medicine

MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals

(2011) F. Marampon et al.   MOLECULAR CANCER THERAPEUTICS

Compensatory Upregulation of Tyrosine Kinase Etk/BMX in Response to Androgen Deprivation Promotes Castration-Resistant Growth of Prostate Cancer Cells

(2010) B. Dai et al.   CANCER RESEARCH

The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy

(2009) Katie DeClerck   Frontiers in Bioscience-Landmark

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

(2008) Bora Gurel et al.   MODERN PATHOLOGY

Modelling Myc inhibition as a cancer therapy

(2008) Laura Soucek et al.   NATURE